Advertisement
Table 3 Clinical characteristics in the two subgroups of prefibrotic and fibrotic PMF
| Prefibrotic PMF | Fibrotic PMF | p value | |
|---|---|---|---|
| Sex | M:F = 11/15 | M:F = 15/31 | n.s. |
| Median age at diagnosis (years) | 43 (20–87) | 61 (27–83) | p = 0.019 |
| WBC at diagnosis (109/l) | 9100 | 8745 | n.s. |
| Hb at diagnosis (g/dl) | 14.6 | 14.3 | n.s. |
| PLT at diagnosis (109/l) | 825000 | 797500 | n.s. |
| Increased LDH | 6/19 (31.6%) | 19/31 (61.3%) | n.s. |
| Splenomegaly (%) | 6 (23%) | 12 (26%) | n.s. |
| JAK2V617-positive (%) | 9 (50%) | 14 (58%) | n.s. |
| History of thrombosis (%) | 6 (23%) | 10 (22%) | n.s. |
| Thrombosis at diagnosis (%) | 4 (15%) | 7 (15%) | n.s. |
| Thrombotic events during follow-up (%) | 6 (23%) | 5 (10%) | n.s. |
| Progression to overt MF (%) | 0 (0%) | 3 (6.5%) | n.s. |
| Dead/Alive | 2/24 | 6/40 | n.s. |
| Conventional Risk (Low/High) | 13/13 | 17/29 | n.s. |
| Cytoreductive therapy (%) | 24 (92%) | 40 (86%) | n.s. |
